0000899243-20-009846.txt : 20200401 0000899243-20-009846.hdr.sgml : 20200401 20200401170802 ACCESSION NUMBER: 0000899243-20-009846 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200330 FILED AS OF DATE: 20200401 DATE AS OF CHANGE: 20200401 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dananberg Jamie CENTRAL INDEX KEY: 0001734424 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38470 FILM NUMBER: 20766174 MAIL ADDRESS: STREET 1: 3280 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Unity Biotechnology, Inc. CENTRAL INDEX KEY: 0001463361 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264726035 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3280 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: (415) 328-5504 MAIL ADDRESS: STREET 1: 3280 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: Cenexys, Inc. DATE OF NAME CHANGE: 20130703 FORMER COMPANY: FORMER CONFORMED NAME: Forge Inc DATE OF NAME CHANGE: 20090504 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-30 0 0001463361 Unity Biotechnology, Inc. UBX 0001734424 Dananberg Jamie C/O UNITY BIOTECHNOLOGY, INC. 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Medical Officer Common Stock, $0.0001 par value 2020-03-30 4 A 0 24255 0.00 A 454702 D Stock Option (Right to Buy) 5.95 2020-03-30 4 A 0 98490 0.00 A 2030-03-29 Common Stock 98490 98490 D Represents Restricted Stock Units ("RSUs") which vest in equal annual installments over a three year period measured from March 30, 2020. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Includes RSUs which vest over time measured from the grant date. Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on March 30, 2020 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. /s/ Tamara L. Tompkins, Attorney-in-Fact for Jamie Dananberg 2020-04-01